A Study of Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
- Cancer
- Breast Cancer
- Locally Advanced Breast Cancer
- Metastatic Breast Cancer
- HER2-Positive Breast Cancer
Completed
- Greece
NCT02595762 ML28801
Trial Summary
This disease registry is a prospective, multicenter non-interventional study designed to observe anti-cancer treatment regimens and clinical outcomes in participants with HER2-positive unresectable locally advanced breast cancer (LABC) or metastatic breast cancer (MBC).
A Disease Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
Eligibility Criteria
- Diagnosis of HER2-positive unresectable LABC or MBC within 6 months prior to enrollment
- None specified
For the latest version of this information please go to www.forpatients.roche.com